Q1 is never a good qtr for most bioland stocks. don't expect that to be diff here. and ceo has said so in prior comments. i think key is keeping the same 2024 overall guidance even w/ soft q1 #s (which i expect). and maybe, just maybe in Q2 or Q3 ER, they can actually beat the guidance and/or raise 2024 overall #s. that would be something. i don't think Q1 # by itself means much as long as overall 2024 # is in tact or even higher than $280 guidance.. (of course if lower guidance, then sure, we will lose even the $3 handle maybe), but i am here for 4-6 qtrs as this will take a lot of time to play out
News 
Market Data 
Discover 
